

13 June 2008

ASX Release

***Intelliheart* research accepted for major heart conferences**

Preliminary research results from Monash University supporting the potential of *Intelliheart* for predicting heart disease has been accepted for presentation at two cardiac conferences this year.

Abstracts covering the interim findings of the research have been accepted for the 56th annual meeting of the Cardiac Society of Australia & New Zealand in Adelaide on August 8-9 and the European Society of Cardiology Congress in Munich, Germany, on September 2.

The Chief Executive Officer of IM Medical, Mr Tommas Bonvino, said the acceptance of the abstracts by two such important groups was gratifying because it showed significant peer acceptance of the direction of the research. "Development of advances in medical technology depends on peer acceptance," he said.

Mr Bonvino said the acceptance of the research abstracts was a positive development for market acceptance of *Intelliheart* as the company expands the product's reach beyond medical clinics and workplace testing.

The Monash research suggests that amongst participants in the study, the risk of heart disease is more than three times greater if they have very stiff arteries or very poor heart rate variability and could be as important as obesity, high blood pressure and diabetes for predicting heart disease in people at high risk.

The healthiest hearts have a variable beat which is diminished in people with heart disease. Arterial stiffness is measured by analysing the pulse waveform of the heartbeat. Standard blood pressure tests measure the peak (systolic) and trough (diastolic) of this waveform in the arm, whereas pulse wave analysis looks at additional measures of arterial stiffness and aims to determine the pressure at the heart, where it matters most.

Mr Bonvino said *Intelliheart* was the only widely available screening test which included the new tests – heart rate variability and arterial stiffness - with a simple, easy-to-use interface and cardiovascular health report.

The Monash research is being done by Dr Dipak Kotecha, a British specialist physician who is in Australia to complete a PhD and being supervised by Dr David Eccleston, a prominent Melbourne cardiologist and Professor Henry Krum of Monash University. Dr Eccleston is a scientific advisor to IM Medical Ltd.

Final results of the Monash research, involving around 500 patients, will be released in early 2009.

Further information: Tommas Bonvino (03) 9860 0900
Media enquiries: Michael Smith 0411 055 306